The project FREE@POC, started in January 2020 and funded by the EIC Pathfinder Open Program, aims to develop an instrument-free molecular diagnostic platform for infectious diseases-testing (HIV, Influenza) in human samples and pathogens (Xylella) in plant tissue.

In this exceptional circumstance, members of the FREE@POC project have promptly decided to direct research-efforts to COVID-19 detection. FORTH partner (coordinator) implemented the portable molecular diagnostic device that was already available in the lab to detect specifically SARS-CoV-2 viral RNA. The 6-sample testing device was used in combination with a newly developed assay (N-gene) based on a patented real-time colorimetric detection method to detect COVID-19 and discriminate between infected and non-infected patients. The device and associated assay was then validated at the Hellenic Pasteur Institute where the high specificity, reliability and quantitative nature of the method was proven with over 60 patients’ samples. UCLH clinical partner is also redirecting research efforts towards COVID-19 detection at the point-of-care. UCLH partner will continue the validation of the above platform with patients’ samples available at the Advanced Pathogen Diagnostics Unit (APDU) of the Hospital.

Key advantages of the newly developed patented methodology are the fast response time (10-20 min); completely contamination-free nature of the assay; portability and simplicity in operation; and, use of a smartphone for data collection with the potential for data transfer and surveillance. Moreover, the use of 3D-printing for manufacturing the device allows for inexpensive and rapid prototyping; the above may provide a quickly deployable solution for relatively large-scale production in emergency cases (outbreaks and pandemics) in both developed and developing countries.

Considering the high importance of a fast action against the virus, investors are now sought to proceed with the fast track certification for this new portable molecular diagnostic platform.